Company Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	42
CEO	Carole Ben-Maimon

Contact Details

Address: Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 United States
Phone	844 511 9056
Website	larimartx.com

Stock Details

Ticker Symbol	LRMR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001374690
CUSIP Number	517125100
ISIN Number	US5171251003
Employer ID	20-3857670
SIC Code	2834

Key Executives

Name	Position
Dr. Carole S. Ben-Maimon M.D.	Chief Executive Officer, President and Director
Michael Celano CPA	Secretary and Chief Financial Officer
Dr. Gopi Shankar M.B.A., Ph.D.	Chief Development Officer
John Berman	Vice President of Finance and Administration
Jennifer Spokes Johansson	Vice President of Legal and Compliance
Dr. Russell G. Clayton Sr., D.O, D.O.	Chief Medical Officer
Francis Michael Conway CPA	Vice President and Controller

Latest SEC Filings

Date	Type	Title
Nov 18, 2024	8-K	Current Report
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Oct 30, 2024	10-Q	Quarterly Report
Oct 30, 2024	8-K	Current Report
Aug 8, 2024	10-Q	Quarterly Report
Aug 7, 2024	8-K	Current Report
Jun 10, 2024	8-K	Current Report

View All SEC Filings